FDA cleared opportunity RevitalVision holds FDA clearance for amblyopia treatment in children over 9 and adults, plus recent CMA approvals for new USA CPT codes. This signals strong regulatory credibility to pursue pediatric ophthalmology clinics, hospitals, and vision therapy centers as primary channels for adoption and reimbursement conversations.

Clinical validation leverage With thousands of clinical trial participants and measurable improvements in visual acuity and contrast sensitivity, target eye care specialists and clinics that emphasize evidence-based results. Use case studies and quantified outcomes to drive trials in clinical settings and support payer discussions.

Revenue channel expansion The platform offers an additional revenue stream for eye care specialists and reduces post-surgery visits for cataract and refractive patients. Focus on ophthalmology practices and surgical centers seeking value-based care models and patient-flow optimization.

Digital sales acceleration SaaS-based digital health model with web commerce (WordPress, Shopfiy, WooCommerce) and digital marketing tools (Google Ads, Google Cloud). Target mid-sized eye care chains and clinics with scalable deployment, trial-to-subscription pilots, and streamlined onboarding for rapid ROI.

Strategic branding and awards Recent industry recognition and a notable Grand Prize highlight differentiated positioning around brain-based, non-invasive technology. Leverage awards in outreach to larger optometry networks (and women in optometry communities) to unlock partnership discussions and expansion into new regions.